Coho Partners Ltd. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 749,585 shares of the medical instruments supplier’s stock after purchasing an additional 147,472 shares during the quarter. Becton, Dickinson and makes up about 3.7% of Coho Partners Ltd.’s investment portfolio, making the stock its 14th largest position. Coho Partners Ltd. owned 0.35% of Becton, Dickinson and worth $146,252,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after purchasing an additional 796,034 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Becton, Dickinson and by 6.5% during the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after purchasing an additional 242,081 shares in the last quarter. Fundsmith LLP grew its holdings in shares of Becton, Dickinson and by 3.2% during the 1st quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after purchasing an additional 71,691 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Becton, Dickinson and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 1,941,743 shares of the medical instruments supplier’s stock worth $355,653,000 after purchasing an additional 151,238 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company (BDX) opened at 193.06 on Monday. The company has a market cap of $43.93 billion, a P/E ratio of 55.91 and a beta of 1.06. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a 50-day moving average price of $199.01 and a 200 day moving average price of $191.58.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

WARNING: “Coho Partners Ltd. Purchases 147,472 Shares of Becton, Dickinson and Company (BDX)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/25/coho-partners-ltd-purchases-147472-shares-of-becton-dickinson-and-company-bdx.html.

Several analysts have recently weighed in on BDX shares. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation reissued a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, July 17th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $200.93.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.